RecruitingNCT05974007

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC: A Retrospective Multi-center Study (NeoR-World)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

1,500 participants

Start Date

Jan 1, 2022

Study Type

OBSERVATIONAL

Summary

Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This is a real-world observational study tracking treatment outcomes in people with non-small cell lung cancer (NSCLC) who received immunotherapy and/or chemotherapy before surgery (called neoadjuvant therapy). Researchers want to understand how these treatments perform outside of controlled clinical trials. **You may be eligible if...** - You are 18–85 years old - You have been diagnosed with non-small cell lung cancer (stage I–III) - You received immunotherapy and/or chemotherapy before having surgery - You are in good enough health to have tolerated surgery - You have at least one measurable area of disease **You may NOT be eligible if...** - You have a history of another cancer - You have been enrolled in another drug-intervention clinical trial - You are currently receiving other anti-cancer treatments outside this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeoadjuvant immunochemotherapy

Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery

DRUGNeoadjuvant chemotherapy

Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery

Locations(1)

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05974007